
Israeli multinational Teva Pharmaceutical has decided to discontinue the development of laquinimod. As such, all rights for the orally administered …
Teva and Active Biotech’s oral MS drug laquinimod has failed to meet its primary endpoint in a phase III trial. …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland

